ArticleJournal of family medicine and primary care2025
Effect of COVID-19 on hematological parameters and subsequent risk of anemia and bleeding in middle-aged and elderly patients with type 2 diabetes.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global coronavirus disease 2019 (COVID-19) outbreak has resulted in a significant number of infections, particularly among individuals with type 2 diabetes, who are at an increased risk. Our goal was to examine how COVID-19 has affected hematological parameters and coagulation markers in elderly patients diagnosed with type 2 diabetes. Methods: The study conducted at tertiary-care hospitals in Tabuk focused on patients with type 2 diabetes mellitus who were also infected with COVID-19. The research included patients aged 45 and older, all of whom had at least 6 months of a type 2 diabetes diagnosis. Patients were excluded from the study if they had active malignancies, recent changes in their antidiabetic medications, severe infections or surgeries, or decompensated liver disease or heart failure. Results: The study included 65 patients. During the COVID-19 pandemic, patients with type 2 diabetes exhibited a notable decrease in red blood cell count, hemoglobin concentration, hematocrit value, and platelet count, accompanied by a significant increase in red cell distribution width, mean platelet volume, prothrombin time, and activated partial thromboplastin time. Following the complete recovery of patients from COVID-19, all hematological parameters reverted to their pre-COVID-19 infection levels. Conclusion: Patients diagnosed with type 2 diabetes and COVID-19 may experience hematological dysregulation, characterized by decreased red blood cell counts, hemoglobin levels, and hematocrit values, predisposing them to anemia. Additionally, they are at an increased risk of bleeding due to reduced platelet count, prolonged prothrombin time, and activated partial thromboplastin time. The results are not affected by gender.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.